First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with advanced prostate cancer that has not yet metastasized will be ...

Orion announced today that the estimated primary completion date for the joint Phase III clinical trial ARAMIS with darolutamide (NCTNCT02200614) by Orion and Bayer has been updated in the ...

Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...

PHILADELPHIA – Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had clinical outcomes similar to those observed in the ...

SAN FRANCISCO — Treatment with the investigational agent darolutamide (Bayer/Orion) significantly extended metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer ...

On July 30th, 2019, the FDA approved NUBEQA ® (darolutamide) based on the ARAMIS trial, a randomized, double-blind, placebo-controlled, multi-center Phase III study, which evaluated the safety and ...

Active surveillance provides an important alternative to immediate treatment for early-stage, low-ri Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in ...

Darolutamide (Nubeqa) was linked with a decrease in locally invasive procedures, as well as local urinary and bowel symptoms, in patients with nonmetastatic (nm) castration-resistant prostate cancer ...

The appraisal committee considered evidence submitted by Bayer, a review of this submission by the evidence review group (ERG), NICE's technical report, and responses from stakeholders. See the ...

Orion Corporation Press Release 5 February 2019 at 3.00 p.m. EET Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study First presentation of data from the ...